Health Tech Capitol | Uncategorized
1
archive,paged,category,category-uncategorized,category-1,paged-14,category-paged-14,tribe-no-js,tribe-bar-is-disabled,ajax_fade,page_not_loaded,,qode-child-theme-ver-1.0.0,qode-theme-ver-9.3,wpb-js-composer js-comp-ver-4.12,vc_responsive

Uncategorized

Propeller Health is partnering with Orion Corporation, a digital therapeutics company, to connect its Easyhaler line of inhalers for asthma and COPD to Propeller’s digital medicine platform. “This partnership with Orion is another significant step toward reducing the burden of chronic respiratory disease for people around the world,”...

Madison-based software firm ImageMoverMD Inc. has raised a $4 million funding round, the company announced today. Founded in 2014 by Dr. Richard Bruce and Dr. Gary Wendt, ImageMover has developed a medical imaging software that integrates images with electronic health records. Using the ImageMover platform, a doctor could...

MADISON, Wis.--(BUSINESS WIRE)--Redox today announced that it is integrating with Microsoft Teams to enable secure, bidirectional data exchange with electronic health record (EHR) software at provider organizations using the FHIR (Fast Healthcare Interoperability Resources) standard. As a result, clinicians and caregivers can easily communicate patient data on the...

MADISON, WI – A diverse, exciting group of Greater Madison healthtech companies will showcase their innovation at the 2019 HIMSS Global Conference & Exhibition taking place Feb. 11-15 in Orlando. The annual conference brings together more than 45,000 health information and technology professionals from around...

MADISON, Wis. -- Dianomi Therapeutics Inc., a biopharmaceutical company focused on osteoarthritis and pain with technology licensed from the Wisconsin Alumni Research Foundation (WARF), has established a partnership with and received an investment of $3 million from Ligand Pharmaceuticals. The partnership focuses on Dianomi's proprietary Mineral...

MADISON, Wis.--Invenra and WARF (Wisconsin Alumni Research Foundation) today announced they have entered into a collaboration to discover and develop a bispecific antibody therapeutic for the treatment of neuroblastoma, a cancer that is the third most common childhood cancer, after leukemia and brain tumors. The...

MADISON, Wis.--Promega Corporation announced today it has signed a non-exclusive license agreement with the Broad Institute of MIT and Harvard to sell tools and reagents for CRISPR-Cas9 gene editing, providing scientists new tools for interrogating endogenous biology. Under the agreement, Promega will combine CRISPR-Cas9 technology...